Encapsulation of Recombinant Adenovirus into Alginate Microspheres Circumvents Vector-specific Immune Response

Overview

Journal Gene Ther

Date 2002 Nov 29

PMID 12457287

Citations 38

Authors

G Sailaja

H HogenEsch

A North

J Hays

S K Mittal

Affiliations

Soon will be listed here.

Abstract

Pre-existing immunity against adenoviruses may compromise the efficacy of adenoviral vectors for vaccination and gene therapy. The purpose of this study was to determine whether encapsulation of adenovirus recombinants into biodegradable alginate microparticles could circumvent the vector-specific immune response. Mice were immunized either intranasally (i.n.) or intraperitoneally (i.p.) with human adenovirus type 5 (HAd5), resulting in the development of virus-specific antibodies. Immunized and nai;ve mice were inoculated with AdCA36lacZ (an E1-deleted HAd5 recombinant containing the bacterial beta-galactosidase (LacZ) gene), encapsulated (E) into alginate microparticles, or nonencapsulated (NE) ie, as a virus suspension. LacZ expression in animals immunized once (1x) or twice (2x) with HAd5 and subsequently inoculated with NE-AdCA36lacZ (NE-Z) was significantly (P<0.001) reduced compared to those levels observed in NE-Z inoculated nai;ve mice, suggesting that the immune response against the vector adversely affected transgene expression. In contrast, there was only slight reduction (P>0.05) in LacZ expression in mice immunized 1x or 2x with HAd5 that were subsequently inoculated with E-AdCA36lacZ (E-Z) compared to those levels obtained in E-Z inoculated nai;ve animals. Similar results were obtained with i.n. or i.p. inoculated animals. These results indicate that microencapsulation of recombinant adenovirus effectively circumvented the vector-specific immune response.

Citing Articles

The Immune System-A Double-Edged Sword for Adenovirus-Based Therapies.

Wallace R, Bliss C, Parker A Viruses. 2024; 16(6).

PMID: 38932265 PMC: 11209478. DOI: 10.3390/v16060973.

An intranasal combination vaccine induces systemic and mucosal immunity against COVID-19 and influenza.

Xing M, Hu G, Wang X, Wang Y, He F, Dai W NPJ Vaccines. 2024; 9(1):64.

PMID: 38509167 PMC: 10954707. DOI: 10.1038/s41541-024-00857-5.

Manganese Mineralization of Pathogenic Viruses as a Universal Vaccine Platform.

Shi P, Xu Y, Zhu Z, Zhou C, Wu M, He Y Adv Sci (Weinh). 2023; 10(33):e2303615.

PMID: 37867242 PMC: 10667830. DOI: 10.1002/advs.202303615.

Adenoviral Vector-Based Vaccine Platform for COVID-19: Current Status.

Chavda V, Bezbaruah R, Valu D, Patel B, Kumar A, Prasad S Vaccines (Basel). 2023; 11(2).

PMID: 36851309 PMC: 9965371. DOI: 10.3390/vaccines11020432.

Significance of Preexisting Vector Immunity and Activation of Innate Responses for Adenoviral Vector-Based Therapy.

Wang W, Sayedahmed E, Mittal S Viruses. 2022; 14(12).

PMID: 36560730 PMC: 9787786. DOI: 10.3390/v14122727.

References

Dai Y, Schwarz E, Gu D, Zhang W, Sarvetnick N, Verma I . Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: tolerization of factor IX and vector antigens allows for long-term expression. Proc Natl Acad Sci U S A. 1995; 92(5):1401-5. PMC: 42527. DOI: 10.1073/pnas.92.5.1401. View

Yang Y, Nunes F, Berencsi K, Furth E, Gonczol E, Wilson J . Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc Natl Acad Sci U S A. 1994; 91(10):4407-11. PMC: 43794. DOI: 10.1073/pnas.91.10.4407. View

Bramson J, Graham F, Gauldie J . The use of adenoviral vectors for gene therapy and gene transfer in vivo. Curr Opin Biotechnol. 1995; 6(5):590-5. DOI: 10.1016/0958-1669(95)80097-2. View

Kay M, Holterman A, Meuse L, Gown A, Ochs H, Linsley P . Long-term hepatic adenovirus-mediated gene expression in mice following CTLA4Ig administration. Nat Genet. 1995; 11(2):191-7. DOI: 10.1038/ng1095-191. View

Crystal R . Transfer of genes to humans: early lessons and obstacles to success. Science. 1995; 270(5235):404-10. DOI: 10.1126/science.270.5235.404. View

Mittal S, Middleton D, Tikoo S, Babiuk L . Pathogenesis and immunogenicity of bovine adenovirus type 3 in cotton rats (Sigmodon hispidus). Virology. 1995; 213(1):131-9. DOI: 10.1006/viro.1995.1553. View

Imler J . Adenovirus vectors as recombinant viral vaccines. Vaccine. 1995; 13(13):1143-51. DOI: 10.1016/0264-410x(95)00032-v. View

Walter J, You Q, Hagstrom J, Sands M, High K . Successful expression of human factor IX following repeat administration of adenoviral vector in mice. Proc Natl Acad Sci U S A. 1996; 93(7):3056-61. PMC: 39760. DOI: 10.1073/pnas.93.7.3056. View

Smith T, White B, Gardner J, Kaleko M, McClelland A . Transient immunosuppression permits successful repetitive intravenous administration of an adenovirus vector. Gene Ther. 1996; 3(6):496-502. View

10.

Dong J, Wang D, van Ginkel F, Pascual D, Frizzell R . Systematic analysis of repeated gene delivery into animal lungs with a recombinant adenovirus vector. Hum Gene Ther. 1996; 7(3):319-31. DOI: 10.1089/hum.1996.7.3-319. View

11.

Guerette B, Vilquin J, Gingras M, Gravel C, Wood K, Tremblay J . Prevention of immune reactions triggered by first-generation adenoviral vectors by monoclonal antibodies and CTLA4Ig. Hum Gene Ther. 1996; 7(12):1455-63. DOI: 10.1089/hum.1996.7.12-1455. View

12.

Leinwand L, Gall J, Bloom B . Circumventing the immune response to adenovirus-mediated gene therapy. Gene Ther. 1996; 3(2):154-62. View

13.

Mack C, Song W, Carpenter H, Wickham T, Kovesdi I, HARVEY B . Circumvention of anti-adenovirus neutralizing immunity by administration of an adenoviral vector of an alternate serotype. Hum Gene Ther. 1997; 8(1):99-109. DOI: 10.1089/hum.1997.8.1-99. View

14.

Periwal S, Speaker T, Cebra J . Orally administered microencapsulated reovirus can bypass suckled, neutralizing maternal antibody that inhibits active immunization of neonates. J Virol. 1997; 71(4):2844-50. PMC: 191409. DOI: 10.1128/JVI.71.4.2844-2850.1997. View

15.

Kaplan J, Smith A . Transient immunosuppression with deoxyspergualin improves longevity of transgene expression and ability to readminister adenoviral vector to the mouse lung. Hum Gene Ther. 1997; 8(9):1095-104. DOI: 10.1089/hum.1997.8.9-1095. View

16.

Addison C, Hitt M, Kunsken D, Graham F . Comparison of the human versus murine cytomegalovirus immediate early gene promoters for transgene expression by adenoviral vectors. J Gen Virol. 1997; 78 ( Pt 7):1653-61. DOI: 10.1099/0022-1317-78-7-1653. View

17.

Ilan Y, Jona V, Sengupta K, Davidson A, Horwitz M, Roy-Chowdhury N . Transient immunosuppression with FK506 permits long-term expression of therapeutic genes introduced into the liver using recombinant adenoviruses in the rat. Hepatology. 1997; 26(4):949-56. DOI: 10.1002/hep.510260422. View

18.

Lomotan E, Brown K, Speaker T, Offita P . Aqueous-based microcapsules are detected primarily in gut-associated dendritic cells after oral inoculation of mice. Vaccine. 1997; 15(17-18):1959-62. DOI: 10.1016/s0264-410x(97)00108-4. View

19.

Ilan Y, Sauter B, CHOWDHURY N, Reddy B, Thummala N, Droguett G . Oral tolerization to adenoviral proteins permits repeated adenovirus-mediated gene therapy in rats with pre-existing immunity to adenoviruses. Hepatology. 1998; 27(5):1368-76. DOI: 10.1002/hep.510270525. View

20.

Guibinga G, Lochmuller H, Massie B, Nalbantoglu J, Karpati G, Petrof B . Combinatorial blockade of calcineurin and CD28 signaling facilitates primary and secondary therapeutic gene transfer by adenovirus vectors in dystrophic (mdx) mouse muscles. J Virol. 1998; 72(6):4601-9. PMC: 109975. DOI: 10.1128/JVI.72.6.4601-4609.1998. View